ESMO Media Releases

Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017.

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

You are still on time to register as Press representative for the ESMO Immuno Oncology Congress 2017 to be held in Geneva, 7-10 December 2017.

Since its inauguration in 2015, ESMO Asia Congress has garnered attention and significant interest from cancer experts and researchers not only in Asia but around the world. This year, the Congress is endorsed by twenty-one oncology societies across Asia and has attracted close to 3000 participants. 

A randomised trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine. 

Education conducted by civil society can play an important role in filling breast cancer policy gaps and advancing cancer control, including advanced breast cancer, researchers report at the ESMO Asia 2017 Congress.

A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.

Just one in five Indonesian women are aware of cervical cancer screening, according to a study presented at the ESMO Asia 2017 Congress.

A study in Myanmar has found that all mouth cancer patients use smokeless tobacco, researchers report at the ESMO Asia 2017 Congress. Betel quid chewing often starts in adolescence and is associated with smoking and drinking alcohol, which are also risk factors for oral cancer.

A study that looked at mainstreaming genetic counselling for ovarian cancer to support screening programmes in Malaysia was presented at the ESMO Asia 2017 Congress.

Researchers have explored the analysis of mutations in cerebrospinal fluid of lung cancer patients with brain metastases in a study presented at the ESMO Asia 2017 Congress.